🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congress is considering cuts to Medicaid during its budget reconciliation process. 70 million ppl receive health coverage under Medicaid, including those w/ cancer. We must #ProtectMedicaid! #ASCOAdvocacy Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd

For individuals with cancer, diseases in which timely diagnosis can be essential for survival, Medicaid coverage is often the key to accessing necessary tests + biopsies that are rarely covered in an ER under EMTALA. Urge Congress to #SaveMedicaid #ProtectMedicaid ANCO

Feeling inspired & grateful to be surrounded by such incredible CHANGEMAKERS in the lung cancer community! #lcsm

Hangout with these cool cats ?! YES Talk about creative ways to engage with patients, community and other oncologists?! YES Win win in my book! #LCSM #TOTL #SOME Balazs Halmos Eric K. Singhi, MD Dr. Estela Rodriguez Ana I. Velázquez Mañana, MD, MSc, FASCO Chul Kim Mara Antonoff, MD, FACS Fawzi Abu Rous, MD Dave Bjork

. #Medicaid provides LIFE SAVING access to healthcare and preventive care to millions of Americans! I urge #Congress members to #ProtectMedicaid If we are serious about Making America Healthy Again and having Americans be HEALTHY, working, and productive members of society they

@imleftylimbaugh Republicans against Trump No scientific data supports the claim that the MMR vaccine contains "millions of particles" from aborted fetal tissue or "millions of DNA fragments." The vaccine is produced using fetal cell lines from the 1960s, but purification removes fetal cells, leaving only trace DNA

Early data on lazertinib in uncommon #EGFR mutant NSCLC JTO & JTO CRR. In 36 pts, RR 50% with mPFS 10.8m, mDOR 15.1m. By mutation, G719X RR 61%, S768I RR 60%, L861Q RR 58%. jto.org/article/S1556-…

3️⃣ Weeks to go for #ASCO25 ! The schedule can be so overwhelming.. Here is my suggested schedule for thoracic trainees. 📆Start making your schedule in the @asco app today and bring comfortable 👟 @hemoncfellows @hemoncmiami #lcsm

🚨 New in JAMA Internal Medicine In this Special Communication, we highlight critical gaps in #EmergencyMedicaid and other state policies designed to support access to basic medical care for undocumented immigrants in the United States. bit.ly/3GKCy8a

Telisotuzumab vedotin is now U.S. FDA approved in previously treated c-Met overexpressing mNSCLC, PhII #LUMINOSITY : - ORR: 28.6% + mOS 14.5mos  - ORR 34.6% + mOS 14.6mos in cMET high - ORR 22.9% + mOS 14.2mos in cMET intm. - AEs: Neuropathy, edema, fatigue #lcsm #OncTwitter

So many abstracts so little time⌚! Here are #ASCO25 Top Lung Cancer Abstract Presentations to watch for -Part 1 Not a lot of new drugs but important updates on #perioperative and #targetedtherapy trials. Full abstracts available 5/22. #CM77T #CM816, #NEOADAURA, #ALNEO,

Don’t be fooled — DEI is NOT eating up 40% of the NIH budget. What is happening? Massive cuts to the NIH are hurting real medical research, American innovation, and thousands of jobs. If we want to bring manufacturing back, grow the economy, and keep America first in science

Thank you Binay Shah, MD, MHA Jonathan Riess, MD MS Binaytara for inviting me to #SFLung25. Enjoyed meeting and learning from wonderful colleagues Matthew Gubens Surbhi Singhal Jyoti Malhotra Lei Deng, MD (He/Him) Ana I. Velázquez Mañana, MD, MSc, FASCO Collin Blakely MD, PhD Tina Li Dron Gauchan Natalia Colocci, Kim-Son Nguyen Sutter Health

💉Immunotherapy innovations at #ASCO25 ASCO From bispecifics & mRNA to engineered bacteria & CAR-T in solid tumors: 🧿 LBL-024 (PD-L1/4-1BB) 🧿 BNT142 (CLDN6 mRNA bispecific) 🧿 IBI363 (PD-1/IL-2α bispecific) 🧿 WT1 Bactovaccine 🧿 EpCAM CAR-T 🧿 TCR-T for PRAME OncoAlert

My husband was already metastatic when he was diagnosed with cancer. Cancer screening is amazing & necessary, but aggressive cancers can grow (& spread) fast. Even if you never ignore symptoms & get superlative healthcare you can still end up with Stage IV cancer. It is awful.

🚨Mark your calendars for the ASCO TECAG town hall on ways to navigate #ASCO25! From logistics, to intentional planning and to enjoyment! 💫"So You’re Going to the ASCO Annual Meeting… What to Do to Make the Most of It" 📅 Thu 5/22 3-4 pm ET 👉Register tinyurl.com/33bbtkzj

Flatiron analysis of 34,510 pts with NSCLC on biomarker testing JCO Oncology Practice by Sandip Patel MD FASCO. Steady rise in biomarker testing: in 2023, 89% tested for #EGFR and 88% for #ALK. Not all receive targeted therapy though: only 84% of ALK+ receive an ALK TKI. ascopubs.org/doi/10.1200/PO…

🚨New from ASCO: The ASCO Guidelines Assistant, a new generative AI tool developed in collaboration with @GoogleCloud, more quickly connects ASCO members with timely and trustworthy information. #ASCO25 Learn more: brnw.ch/21wSPeh

That's the world's literature on ivermectin in advanced cancer. 8 pts with TNBC getting ICI + ivermectin, 1 response (same rate as ICI alone, in other trials), avg PFS of 2.5 m. So, at present, there is no evidence for meaningful clinical activity of ivermectin in cancer.

This is great and exciting data — but we need caution before assuming it translates to real-world settings. These pts had surgery performed by highly skilled thoracic surgeons at high-volume, top-tier cancer centers. Yet, ~25% didn’t get surgery, and 2–3 didn’t have R0